Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GYRE Gyre Therapeutics	$7.42 +0.5%	$9.06	$6.11 ▼ $19.00	$691.93M	1.79	130,821 shs	1.05 million shs
IMNM Immunome	$8.77 -0.2%	$8.61	$5.15 ▼ $16.81	$764.84M	1.94	900,000 shs	1.07 million shs
PHAT Phathom Pharmaceuticals	$9.74 +2.0%	$5.75	$2.21 ▼ $19.71	$666.72M	0.08	1.53 million shs	1.23 million shs
PROK ProKidney	$0.67 -7.5%	$0.80	$0.46 ▼ $2.59	$211.59M	1.35	703,482 shs	12.36 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GYRE Gyre Therapeutics	+0.54%	-8.05%	-21.40%	-18.55%	-20.73%
IMNM Immunome	-0.23%	+0.23%	+1.62%	+25.46%	-27.10%
PHAT Phathom Pharmaceuticals	+1.99%	-6.53%	+138.73%	+47.58%	-4.70%
PROK ProKidney	-7.50%	+1.30%	-5.26%	-26.52%	-70.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GYRE Gyre Therapeutics	0.2724 of 5 stars	0.0	2.0	2.5	0.8	0.0
IMNM Immunome	2.2064 of 5 stars	3.5	2.0	2.2	2.5	0.0
PHAT Phathom Pharmaceuticals	3.8356 of 5 stars	4.5	1.0	2.5	5.0	0.6
PROK ProKidney	2.5247 of 5 stars	3.2	0.0	3.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GYRE Gyre Therapeutics	3.00	Buy	N/A	N/A
IMNM Immunome	3.00	Buy	$23.33	166.06% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	79.67% Upside
PROK ProKidney	2.33	Hold	$4.50	572.95% Upside

Current Analyst Ratings Breakdown

Latest PROK, IMNM, GYRE, and PHAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
5/13/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00 ➝ $21.00
5/2/2025	PHAT Phathom Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $5.00
5/2/2025	PHAT Phathom Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $12.00
5/2/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $20.00
4/21/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
4/17/2025	PHAT Phathom Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$12.00 ➝ $10.00
4/9/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
4/2/2025	IMNM Immunome	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$23.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GYRE Gyre Therapeutics	$105.76M	6.58	$0.20 per share	37.37	$1.05 per share	7.07
IMNM Immunome	$9.04M	84.41	N/A	N/A	$2.27 per share	3.86
PHAT Phathom Pharmaceuticals	$55.25M	12.31	N/A	N/A	($3.71) per share	-2.63
PROK ProKidney	$80K	2,446.61	N/A	N/A	($3.41) per share	-0.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GYRE Gyre Therapeutics	$12.09M	$0.02	371.19	∞	N/A	7.20%	9.73%	7.66%	8/12/2025 (Estimated)
IMNM Immunome	-$292.96M	-$3.18	N/A	N/A	N/A	-1,875.21%	-71.65%	-60.36%	8/11/2025 (Estimated)
PHAT Phathom Pharmaceuticals	-$334.33M	-$5.24	N/A	N/A	N/A	-422.42%	N/A	-90.11%	8/6/2025 (Estimated)
PROK ProKidney	-$61.19M	-$0.60	N/A	N/A	N/A	N/A	N/A	-15.03%	8/8/2025 (Estimated)

Latest PROK, IMNM, GYRE, and PHAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
5/12/2025	Q1 2025	PROK ProKidney	-$0.16	-$0.13	+$0.03	-$0.13	N/A	$0.23 million
5/9/2025	Q1 2025	GYRE Gyre Therapeutics	$0.03	$0.03	N/A	N/A	$28.40 million	$22.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GYRE Gyre Therapeutics	N/A	3.60	3.19
IMNM Immunome	N/A	10.49	10.49
PHAT Phathom Pharmaceuticals	N/A	3.58	3.54
PROK ProKidney	N/A	10.96	10.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GYRE Gyre Therapeutics	23.99%
IMNM Immunome	44.58%
PHAT Phathom Pharmaceuticals	99.01%
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
GYRE Gyre Therapeutics	10.00%
IMNM Immunome	8.60%
PHAT Phathom Pharmaceuticals	23.00%
PROK ProKidney	41.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GYRE Gyre Therapeutics	40	93.76 million	84.38 million	No Data
IMNM Immunome	40	87.01 million	79.53 million	Optionable
PHAT Phathom Pharmaceuticals	110	69.81 million	53.76 million	Optionable
PROK ProKidney	3	292.70 million	171.26 million	Optionable

PROK, IMNM, GYRE, and PHAT Headlines

Recent News About These Companies

Hennion & Walsh Asset Management Inc. Has $740,000 Stake in ProKidney Corp. (NASDAQ:PROK)

June 8, 2025 | marketbeat.com

ProKidney quarterly loss grows as it nears two key milestones

May 15, 2025 | journalnow.comJ

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights

May 12, 2025 | globenewswire.com

Another Big Office Landlord Tests Sales Climate

May 12, 2025 | bankerandtradesman.comB

PROKIDNEY Earnings Preview: Recent $PROK Insider Trading, Hedge Fund Activity, and More

May 9, 2025 | nasdaq.com

Why ProKidney Corp.’s (PROK) Stock Is Down 6.09%

April 28, 2025 | aaii.comA

Insider Buying: ProKidney Corp. (NASDAQ:PROK) Insider Purchases 387,393 Shares of Stock

April 25, 2025 | insidertrades.com

Why ProKidney Corp.’s (PROK) Stock Is Down 7.90%

April 17, 2025 | aaii.comA

ProKidney Corp. (NASDAQ:PROK) Insider Buys $195,716.65 in Stock

April 17, 2025 | insidertrades.com

Greensboro’s Once Great Win Is Now A ProKidney Failure

April 16, 2025 | rhinotimes.comR

Control Empresarial De Capital Buys 1,032,218 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

April 15, 2025 | insidertrades.com

Why ProKidney Corp.’s (PROK) Stock Is Down 9.90%

April 10, 2025 | aaii.comA

Why ProKidney Corp.’s (PROK) Stock Is Down 14.87%

April 8, 2025 | aaii.comA

ProKidney Corp.

March 30, 2025 | wsj.com

Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation

March 27, 2025 | finance.yahoo.com

Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)

March 21, 2025 | zacks.com

ProKidney reports larger loss in 2024 as production resumes

March 18, 2025 | journalnow.comJ

ProKidney reports FY24 EPS (62c), consensus (59c)

March 17, 2025 | markets.businessinsider.com

ProKidney Corp. Reports 2024 Financial Results and Milestones in Rilparencel Development for Chronic Kidney Disease

March 17, 2025 | quiverquant.comQ

ProKidney Reports Full Year 2024 Financial Results and Business Highlights

March 17, 2025 | globenewswire.com

Why ProKidney Corp.’s (PROK) Stock Is Down 10.96%

February 26, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK, IMNM, GYRE, and PHAT Company Descriptions

Gyre Therapeutics NASDAQ:GYRE

$7.42 +0.04 (+0.54%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$7.42 0.00 (0.00%)

As of 06/27/2025 06:08 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Immunome NASDAQ:IMNM

$8.77 -0.02 (-0.23%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.72 -0.05 (-0.57%)

As of 06/27/2025 05:18 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Phathom Pharmaceuticals NASDAQ:PHAT

$9.74 +0.19 (+1.99%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.66 -0.08 (-0.86%)

As of 06/27/2025 07:55 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

ProKidney NASDAQ:PROK

$0.67 -0.05 (-7.50%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.70 +0.03 (+5.13%)

As of 06/27/2025 07:38 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time